Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis

B.C. Cho; M-J. Ahn; C. Baik; R. García; J.W. Goldman; S-W. Kim; J.S. Lee; M. Nishio; S. Ponce; R. Salgia; S. Teraoka; T. Yoshida; H.A. Yu; H. Ambrose; J. Cosaert; R. Hartmaier; J. Maidment; M. Pluta; I. Okamoto

doi:10.1016/j.annonc.2022.02.022

YUHSpace

BROWSE

0 122

Cited 0 times in

Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis

Authors: B.C. Cho ; M-J. Ahn ; C. Baik ; R. García ; J.W. Goldman ; S-W. Kim ; J.S. Lee ; M. Nishio ; S. Ponce ; R. Salgia ; S. Teraoka ; T. Yoshida ; H.A. Yu ; H. Ambrose ; J. Cosaert ; R. Hartmaier ; J. Maidment ; M. Pluta ; I. Okamoto